Connect with us
The current round has an investment commitment of up to €3 million, which includes the participation of the founding partners. The €7 million will make it...
Ability Pharma has closed 2022 with a turnover of €2.3 million, which translates into an increase of 53% compared to the income of 2021. For its...
Ability Pharma is working on a drug capable of inducing cancer cell death through autophagy. ABTL0812 has demonstrated clinical efficacy in a Phase II clinical trial...
The Spanish company Ability Pharma, specialized in the development of oral anti-cancer compounds, has attracted this funding after receiving a grant of more than $1.19 million...